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Abstract
Purpose The Quality of Life after Brain Injury overall scale (QOLIBRI-OS) measures health-related quality of life (HRQoL) 
after traumatic brain injury (TBI). The aim of this study was to derive value sets for the QOLIBRI-OS in three European 
countries, which will allow calculation of utility scores for TBI health states.
Methods A QOLIBRI-OS value set was derived by using discrete choice experiments (DCEs) and visual analogue scales 
(VAS) in general population samples from the Netherlands, United Kingdom and Italy. A three-stage procedure was used: (1) 
A selection of health states, covering the entire spectrum of severity, was defined; (2) General population samples performed 
the health state valuation task using a web-based survey with three VAS questions and an at random selection of sixteen 
DCEs; (3) DCEs were analysed using a conditional logistic regression and were then anchored on the VAS data. Utility 
scores for QOLIBRI-OS health states were generated resulting in estimates for all potential health states.
Results The questionnaire was completed by 13,623 respondents. The biggest weight increase for all attributes is seen from 
“slightly” to “not at all satisfied”, resulting in the largest impact on HRQoL. “Not at all satisfied with how brain is working” 
should receive the greatest weight in utility calculations in all three countries.
Conclusion By transforming the QOLIBRI-OS into utility scores, we enabled the application in economic evaluations and 
in summary measures of population health, which may be used to inform decision-makers on the best interventions and 
strategies for TBI patients.
Keywords Health-related quality of life · Quality of life after brain injury overall scale (QOLIBRI-OS) · Health utilities · 
Value set · Traumatic brain injury
Introduction
Traumatic Brain Injury (TBI) is generally defined as “an 
alteration in brain function or other evidence of brain 
pathology, caused by an external force” [1]. TBI is one 
of the leading causes of death and disability worldwide 
[2]. Annually, TBI costs approximately $US 400 billion 
worldwide and imposes a massive burden on society [3]. 
Economic evaluations in health care interventions are 
increasingly being used to inform governments, health-
care funders and policy makers and to prioritize resource 
allocation [4]. Nonetheless, for economic evaluations, 
preference-based measures (PBMs) are a requirement [5] 
and values have to be assigned to the health states these 
measures describe [6]. Many popular PBMs are generic. 
However, generic instruments do not always adequately 
assess specific aspects of health-related quality of life 
(HRQoL) that are affected by a disease such as cognition 
[7]. Therefore, generic measures, such as the EuroQol-5D 
(EQ-5D) and Short Form-36 (SF-36), are often combined 
with condition-specific questionnaires. A TBI-specific 
instrument is the Quality of Life after Brain Injury overall 
The members of the CENTER-TBI Participants and Investigators 
has been included in ‘Acknowledgements’ section.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1113 6-020-02583 -6) contains 
supplementary material, which is available to authorized users.
 * Daphne C. Voormolen 
 d.voormolen@erasmusmc.nldd
Extended author information available on the last page of the article
 Quality of Life Research
1 3
scale (QOLIBRI-OS) [8]. The QOLIBRI-OS instrument 
is a disease-specific tool for assessing HRQoL after sus-
taining TBI, which covers areas that are typically affected 
by TBI [9]. It was developed in 2012 and since then has 
been widely applied in TBI [8]. By generating a condition-
specific preference-based measure (CSPBM) for TBI, it 
will potentially provide a more accurate assessment of the 
impact of heterogeneous outcomes after TBI and a more 
sensitive measure of the benefit of interventions.
The QOLIBRI-OS is a non-preference-based instrument 
that yields ordinal data, and therefore has limitations for 
economic evaluation studies. Transforming QOLIBRI-OS 
into utility scores will enable the application in economic 
evaluations and in summary measures of population health 
(e.g. quality-adjusted life years (QALYs)). Furthermore, a 
value set for the QOLIBRI-OS will introduce the ability to 
summarize general population preferences for health states 
that could be experienced by TBI patients and the HRQoL 
of TBI patients can be compared with other (patient) groups.
To be able to use health state values in QALYs calcu-
lations [10], they have to be anchored on a scale from 0 
(dead) to 1 (full health). A less than 0 value is given to health 
states which are reported to be worse than dead. Ultimately, 
a value set can be generated, which means that each item 
level of the QOLIBRI-OS has a weight (utility) assigned to 
it. A lower utility means a higher impact on HRQoL. Each 
QOLIBRI-OS health state can be converted into a single 
summary index value with a value set.
Value sets for generic instruments (e.g. EQ-5D and 
Health Utility Index 2 (HUI2)) [11] are widely available 
and are being used extensively in economic evaluations [12]. 
However, the QOLIRBI-OS currently does not have utili-
ties, which means the instrument cannot be used for QALY 
calculations [13]. To make the QOLIBRI-OS suitable for 
use in economic evaluations, the health states need to be 
valued with a preference-elicitation method. Widely used 
methods are discrete choice experiments (DCE) [14, 15] 
and visual analogue scales (VAS) [16]. The DCE and VAS 
technique are used to quantify health outcomes [17–21]. 
DCEs are based on stated preferences and are seen to be a 
simpler method than the conventional methods such as time 
trade off (TTO) and standard gamble (SG) [22]. The DCE 
approach makes it possible to predict values for alternatives 
in hypothetical situations or conditions that cannot be judged 
in the real world [23]. The VAS is a valuation technique that 
records participants’ views about hypothetical health states 
on a scale from 0 (worst imaginable health state) to 100 (best 
imaginable health state) [16].
The objective of this study was to develop health utility 
indices for the QOLIBRI-OS health states. In order to do 
this, we aimed to develop value sets for the QOLIBRI-
OS in three European countries by the use of a web-
based DCE and VAS valuation study, which will allow 
calculation of utility values for the health states measured 
with the QOLIBRI-OS.
Methods
The QOLIBRI-OS is a short, six-item version of the Qual-
ity of Life after Brain Injury (QOLIBRI), which provides 
a profile of HRQoL in domains typically affected by brain 
injury. It addresses well-being and functioning and the 
psychometric properties have been determined satisfac-
tory to good [8]. The QOLIBRI-OS assesses a single 
overall score, which provides a brief summary measure of 
HRQoL [8]. The six items are satisfaction with physical 
condition; how brain is working, in terms of concentra-
tion, memory and thinking; feelings and emotions; ability 
to carry out day to day activities; personal and social life; 
current situation and future prospects. Responses are on 
a 5-point Likert scale ranging from “not at all satisfied” 
to “very satisfied”. Ultimately, the current situation and 
future prospects item from the QOLIBRI-OS was excluded 
because a general sample might answer this item too sub-
jectively, which may hamper the use of the QOLIBRI-OS 
value set in populations other than TBI patients. By use 
of Rasch analysis, the psychometric validity of the QOLI-
BIR-OS scale was tested and well-functioning items of the 
QOLIBRI-OS were identified, which ultimately resulted 
in measures of item difficulty and fit of the QOLIBRI-OS. 
The scale was examined for redundancy and removing the 
current situation and future prospects item did not change 
the properties of the scale (Online Appendix A). In the 
end, the QOLIBRI-OS scale included 5 items, each with 
5 levels, which are shown in Table 1.
Developing value sets for the QOLIBRI-OS required 
three methodological steps (Fig. 1). Each of these steps is 
described in more detail in the following sections.
Table 1  Five selected items of QOLIBRI-OS
Item levels: 1-Not at all; 2-Slightly; 3-Moderately; 4-Quite; 5-Very
QOLIBRI-OS
1. Satisfied with physical condition
2. Satisfied with how brain is working, in terms of concentration, 
memory and thinking
3. Satisfied with feelings and emotions
4. Satisfied with ability to carry out day to day activities
5. Satisfied with personal and social life
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Step‑by‑step
Step 1: Health state selection
Even after reducing the items from the QOLIBRI-OS from 6 
to 5, the selected items can generate a large number of pos-
sible health states. The 5-item QOLIBRI-OS can generate 
3125  (55) possible health states, since each dimension has 
five levels, and this makes it impossible to ask the respond-
ents for a valuation all of them [13]. We therefore made a 
selection of health states to be used in the health state valu-
ation task. For the DCE valuation of the QOLIBRI-OS, 392 
health states were selected, which were presented in 196 
pairs, based on a method devised by Oppe and van Hout 
[24]. These health states cover the spectrum of severity. For 
this we used a level-balanced design [13], meaning that all 
levels of each item occurred with the same frequency. The 
same 392 states were used in the EuroQol EQ-5D-5L value 
set valuation study [24–26]. The best and worst health states 
plus death were selected for the visual analogue scale (VAS) 
valuation.
Step 2: Health state valuation—study design
During this step a panel of judges evaluated the selected 
health states. The general population was asked to evaluate 
the possible QOLIBRI-OS health states by assuming what 
they would consider their quality of life to be, if they were 
in one of these specific health states. The responses from the 
general population sample were used to generate the health 
state values.
Health state valuation—Survey
The web-based questionnaire included questions regarding 
the demographics of the respondent (e.g. age, sex, educa-
tional and income level, chronic health complaints), six-
teen DCE questions and three VAS questions. The DCE 
pairs were randomly assigned to the participants. During 
this study, no DCE or VAS data were excluded. The survey 
and description of health states were translated from Eng-
lish into Dutch and Italian using translation software and 
subsequently translated back into English. Bilingual native 
speakers verified the translations independently. The panel 
of judges consisted of members of the general public aged 
18 to 75 years from the United Kingdom (UK), Italy and the 
Netherlands, which provided an international spread. The 
samples were also representative of the population in the 
countries with regard to age, gender and education. A total 
number of 13,623 respondents filled out the questionnaire 
(Italy: 5270 respondents; Netherlands 4183 respondents; UK 
4170 respondents). The questionnaires were distributed by 
a market research agency (Survey Sampling International 
(SSI), nowadays called Dynata) via internet during the 
period 29 June till 31 July 2017. A second round of data 
collection took place between 3 February and 16 February 
2018 to collect some more responses for the VAS data, espe-
cially for the health state ‘dead’, and these were all respond-
ents who had already completed the survey the first round 
(recontacts).
Fig. 1  Steps taken to yield a QOLIBRI-OS value set which enables 
calculation of utility weights for the health states measured with this 
instrument. QOLIBRI Quality of Life after Brain Injury, QOLIBRI-
OS Quality of Life after Brain Injury Overall Scale
 Quality of Life Research
1 3
Valuation techniques
The responses from the general population sample reflect 
preferences between different health states [10] and these 
were used to generate and model the value sets.
One of the methods used to evaluate the health states was 
a DCE [27–29], which is an ordinal measurement method. 
With this method, a pair of health states (labelled A and 
B, Fig. 2), with no reference to the duration of the states, 
is presented, and respondents have to decide which health 
state they consider to be better. No indifference option was 
included. The assumption of a DCE is that the choices 
among sets of divergent health states are driven by differ-
ences in the levels of the dimensions from the QOLIBRI-
OS which define the health states. Furthermore, by asking 
respondents to choose between health states with altering 
severity levels and different combinations, the opportunity 
arises to estimate the impact of the preferences based on the 
changes in levels [30]. We used colours in the online survey 
to indicate the severity level of the attribute, ranging from 
green indicating very satisfied to red indicating not at all 
satisfied.
The second method used was the VAS, which is a 
valuation technique that requires participants to score 
the injury stage on a vertical scale graded from 0 (worst 
imaginable health state) to 100 (best imaginable health 
state). As done previously by Stolk et al. [23], a rescaled 
VAS, based on dead and the best and worst health states, 
was developed; health preference valuations of 0 to 100 on 
the VAS were rescaled from 0 to 1. This was done by the use 
of the following formula:
It was necessary to rescale the VAS values in such a way 
that the value for death was explicitly set at 0 and the best 
health state (11,111) to 1 [23].
Step 3. Modelling the DCE health state valuations
Statistical modelling was used to estimate the values for all 
potential health states according to the responses for the 
selected health states. The coefficients for each level and 
attribute were estimated by regression techniques. Whether 
a level has a positive or negative effect on utility depends 
on the sign of the coefficient. The relative importance of 
the level is revealed by the value of the coefficient. A level 
is considered to be important when the coefficient has been 
determined to be statistically significant (p < 0.05) [31]. 
Afterwards, the values for all the health states described by 
the QOLIBRI-OS were generated from these coefficients 
[32]. A utility score for the QOLIBRI-OS health states is 
VAS rescaled = 100 ×
VASmean − VAS dead
VAS 11, 111 − VAS dead
.
Fig. 2  Example of a QOLIBRI-OS DCE question. DCE Discrete Choice Experiment
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generated from the DCE responses anchored on the VAS. 
DCE responses were defined as binary outcomes.
As described by Feng et al. [32], a 20 parameter model 
(4 levels × 5 dimensions = 20 parameters) was generated for 
the QOLIBRI-OS, which estimated four parameters for each 
dimension and one parameter per level, with the “very satis-
fied” level used as the reference. This model allowed for the 
coefficients to differ between dimensions and for the impor-
tance of each level of problems to differ between dimensions 
[32]. Regression models were estimated for the DCE in all 
three countries separately. DCE answers were analysed using 
a conditional logistic regression. Subsequently, we derived 
health state values from the DCE data on the QALY scale 
by anchoring the values on the estimated VAS value for the 
worst state (55,555). The following formula was used for this 
process:
where 20 parameter DCEmodel is the coefficient from the condi-
tional logistic regression DCE model, estimated VASworst state 
is the pooled mean value given to the worst health state by 
all respondents, estimated DCEworst state is the intercept and all 
“not at all” level coefficients from the DCE model summed up, 
which generates a anchored DCEmodel for each attribute and level 
as output. The utilities are based on and have been calculated 
by the use of these anchored DCE coefficients.
In addition, we implemented a generalized additive logistic 
regression using the bamlss package of R [33, 34] to relax the 
assumption of the standard logistic regression on the linear 
relationship between the predictors and the log-odds of the 
outcome. We compared the non-parametric model specifying 
an additive (but otherwise unknown) utility function to the 
standard model assuming linear utility.
Statistical analysis
For the statistical analyses, responses on the QOLIBRI-OS 
were recoded with 1 reflecting “very satisfied” and 5 reflect-
ing “not at all satisfied” (similar to the convention used for the 
EQ-5D). Therefore, 11,111 was seen as the ‘best health state’ 
and 55,555 as the ‘worst health state’.
Rasch analysis was performed using Winsteps 3.92 (Win-
steps.com, Chicago Illinois, USA).
All other analyses were performed using SPSS version 24 
for Windows (IBM SPSS Statistics, SPSS Inc, Chicago, IL) 
and R (R Core Team (2013). R: A language and environment 
for statistical computing. R Foundation for Statistical Comput-
ing, Vienna, Austria).
anchored DCEmodel =
20 parameter DCEmodel × estimated VASworst state
estimated DCEworst state
,
Results
Study population
The characteristics of the survey respondents are shown in 
Table 2. A total of 13,623 respondents divided over three 
countries completed the questionnaire. The median age of 
the respondents was 45 years old. Approximately half of 
the respondents (51.2%; N = 6981) were employed and 15% 
(N = 2068) were retired. One out of two respondents have 
experienced serious illness in their immediate family and/
or reported to have chronic health complaints.
DCE data
An upward trend was shown in probability of respondents 
choosing health state A when the difference in sum score 
of health state A and B (e.g. probability of choosing health 
state 11,111; sum score = 5 over health state 123,45; sum 
score = 15) becomes bigger and more positive, which is what 
was expected (Online Appendix B).
VAS data
Table 3 shows the summary statistics for the three VAS 
health states considering the QOLIBRI-OS data. The low-
est mean value was 38.01 (health state dead) and highest 
mean value was 81.49 (health state 11,111, e.g. very satis-
fied with every attribute). As expected, when the summary 
score of the of the health state decreased (e.g. severity of 
health state becomes lower), which means the health state 
was comprised of lower attribute levels, the utility mean 
increased.
Value sets
Table 4 shows the 20 parameters model per country for the 
QOLIBRI-OS which was based on the conditional logistic 
regression for the DCE data and the anchoring of the DCE 
coefficients. For all respondents and both the Netherlands 
and Italy, the lowest estimate for the DCE and anchored 
DCE data was found for ‘Quite satisfied with feelings and 
emotions’ and the highest estimate for ‘Not at all satisfied 
with how brain is working in terms of concentration, mem-
ory and thinking’. When looking at the model specifically for 
the UK, the lowest estimate was found for ‘Moderately satis-
fied with personal and social life’ and the highest for ‘Not 
at all satisfied with how brain is working in terms of con-
centration, memory and thinking’. The biggest increase in 
weight for all attributes is seen from level four (slightly satis-
fied) to level five (not at all satisfied). Table 5 introduces an 
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example for the QOLIBRI-OS value set based on the DCE 
and anchored DCE models. This enables the calculation of a 
utility weight per health state, which is how the utilities for 
the QOLIBIR-OS data can be obtained. The utility scores of 
the anchored DCE model of the QOLIBRI-OS range from 
0.383 for health state 55,555 to 1.0 for health state 11,111. 
Table 6 shows an example of values for a mild, moderate 
and severe health state. Generally speaking, Italians value 
these health states lower compared to their counterparts 
in UK and the Netherlands. Online Appendix C shows the 
non-parametric models per country for the QOLIBRI-OS 
and Online Appendix D shows an example of values for a 
mild, moderate and severe health state based on the non-
parametric models.  
Discussion
Our study demonstrates the first value sets for the QOLIBRI-
OS. The main outcomes according to the preferences of our 
general sample suggested the biggest increase in weight was 
found when making the step from level slightly satisfied to 
Table 2  Characteristics of the 
study population
a Data are displayed as median, with the first and third quartile given within brackets
b Education was divided up in low (junior school), middle (comprehensive school) and high (college and 
university)
c Work status was categorized as employed (employee and self-employed), unemployed (consisting out of 
work for more than and less than 1 year), looking after others (e.g. a carer or parent), a student, retired and 
unable to work
d E.g. carer or parent
e Income was grouped as follows low (UK; less than £14,000, Italy and the Netherlands; less than €20,000), 
middle (UK; £14,000-£27,999, Italy and the Netherlands; €20,000-€39,999) and high (UK; more than 
£27,999, Italy and the Netherlands; more than €39,999)
f Chronic health complaints were defined as asthma, chronic bronchitis, severe heart disease, consequences 
of a stroke, diabetes, severe back complaints, arthrosis, rheumatism, cancer, memory problems due to neu-
rological disease/dementia, memory problems due to ageing, depression or anxiety disorder, and other 
chronic health complaints
All respondents UK The Netherlands Italy
(N = 13,623) (N = 5270) (N = 4183) (N = 4170)
N (%) N (%) N (%) N (%)
Agea (years) 45 [33–57] 44 [32–57] 46 [33–58] 45 [34–57]
Gender (male) 6736 (49.4%) 2597 (49.3%) 2069 (49.5%) 2070 (49.6%)
Educationb
 Low 3797 (27.9%) 1205 (22.9%) 1232 (29.5%) 1360 (32.6%)
 Middle 6499 (47.7%) 2265 (43.0%) 1901 (45.4%) 2333 (55.9%)
 High 3327 (24.4%) 1800 (34.2%) 1050 (25.1%) 477 (11.4%)
Work  statusc
 Employed 6981 (51.2%) 2759 (52.4%) 2214 (52.9%) 2008 (48.2%)
 Unemployed 1915 (14.1%) 475 (9.0%) 447 (10.7%) 993 (23.8%)
 Looking after  othersd 699 (5.1%) 358 (6.8%) 177 (4.2%) 164 (3.9%)
 Student 849 (6.2%) 294 (5.6%) 270 (6.5%) 285 (6.8%)
 Retired 2068 (15.2%) 855 (16.2%) 545 (13.0%) 668 (16.0%)
 Unable to work 1111 (8.2%) 529 (10.0%) 530 (12.7%) 52 (1.2%)
Annual household  incomee
 Low 3131 (23.0%) 1126 (21.4%) 759 (18.1%) 1247 (29.9%)
 Middle 3315 (24.3%) 1604 (30.4%) 728 (17.4%) 983 (23.6%)
 High 5076 (37.3%) 1994 (37.8%) 1787 (42.7%) 1295 (31.1%)
 Do not know/do not want to tell 2100 (15.4%) 546 (10.4%) 909 (21.7%) 645 (15.5%)
Experience of serious illness
 In you yourself (yes) 3517 (25.8%) 1834 (34.8%) 1068 (25.5%) 615 (14.7%)
 In your immediate family (yes) 7066 (51.9%) 3231 (61.3%) 2864 (68.5%) 971 (23.3%)
 In caring for others (yes) 3224 (23.7%) 1689 (32.0%) 924 (22.1%) 611 (14.7%)
 Chronic health complaints (yes)f 6896 (50.6%) 2778 (52.7%) 2223 (53.1%) 1895 (45.4%)
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level not at all satisfied within an attribute, which results 
in the largest impact on HRoQL. This is also in line with 
previous EQ-5D value set research [32]. Additionally, it was 
also found that ‘Not at all satisfied with how brain is work-
ing in terms of concentration, memory and thinking’ should 
receive the greatest weight in utility calculations in all three 
countries.
When looking at the face validity of the value set, it was 
shown that a lower level of satisfaction within a health state 
also corresponded to a lower utility.
Strengths of our study include the representativeness of 
the study sample and the large number of survey respondents 
included in our survey. A general population sample was 
used instead of a brain injury group, because then the benefit 
gained has been determined from a public perspective, who 
ultimately are the taxpayers and potential patients.
During this study, DCEs were used and as mentioned in 
previous research, this valuation technique has advantages 
in measuring health state valuations over methods such as 
standard gamble (SG) and time trade off (TTO) in terms 
of simplicity [35] and understandability. There are several 
methods of administration to conduct health state valuation 
studies, such as face-to-face using paper-and-pencil methods 
and web-based questionnaires. The choice for a web-based 
survey during this study also implied using health state 
valuation methods that were amenable to online adminis-
tration, in this case DCEs and VAS. Compared to personal 
interviews, web-based surveys are equipped to get answers 
from large samples in a relatively short time, have a flex-
ible sampling frame, enable a range of background char-
acteristics of non-respondents to be obtained, the order of 
the questions can be randomized, allow complex routing of 
questions, the time it takes a respondent can be recorded, 
and the errors associated with data entry are minimized [36]. 
Some limitations considering DCE research are the fact that 
a main effects only design, assuming that all attributes were 
value-independent of each other (i.e. all interactions between 
attributes were zero) was used. This may, however, be 
reasonable since main effects typically account for 70–90% 
of the explained variance in DCE [37]. Additionally, the 
complexity of a DCE can potentially cause some extra selec-
tion bias compared with general questionnaire surveys [38]. 
Furthermore, we have also encountered some limitations 
specific to our study. To ultimately get to five items for the 
QOLIBRI-OS, we based eliminating the last item on sub-
jective researcher judgement, which could potentially lead 
to bias. Considering it was a web-based survey, we had no 
control on checking if respondents completely understood 
the task at hand. For future studies it would be advisable to 
build in a tool, to be able to check answers while respond-
ents are taking the survey, for example to check if they are 
using the VAS correctly and are not turning it upside down. 
Additionally, face-to-face surveys will deliver higher qual-
ity data, but also require larger monetary resources. How-
ever, web-based is the mostly used administration method 
in DCE research, especially because of the high costs asso-
ciated with the face-to-face method. We based our health 
states and pairs on previous EQ-5D research; however, it 
could be that for the QOLIBRI-OS instrument different 
health states should have been asked and for future research 
it would be advised to develop an experimental design where 
the pairs of health states are selected specifically for the 
QOLIBIR-OS. Another problem is that the respondents saw 
a complete ‘clean’ VAS for every new question. In a situa-
tion where their given answers are shown on the scale dur-
ing the following questions, the respondents can scale their 
own answers more easily, which ultimately leads to a better 
scale division. The VAS and DCE are different tasks; what 
people imagine when they use the VAS may vary relative 
to a DCE. Using the VAS to scale, such as was done in 
this study, makes mathematical sense, but does it also make 
sense when using it to scale coefficients giving utilities? In 
addition, the worst health state (health state 55,555, e.g. not 
at all satisfied with every attribute) was given a mean VAS 
value of 54.64, which was expected to be lower, and could 
influence the rescaling. Furthermore, VAS scores used for 
rescaling in this study were not based on country-specific 
data due to small sample size. Future research could solve 
these limitations linked to the VAS values used in this 
study by doing a small TTO valuation task in each of the 
three countries, to provide anchors for the DCE scale. In 
addition, for the UK value set, an inconsistent coefficient 
in the final algorithm (“moderately satisfied with personal 
and social life”) was reported, which should be looked at 
in more detail in future research. Moreover, the DCE and 
VAS questions were completely randomized. The quality 
of the data would have most likely been higher, if we asked 
the DCE and VAS questions in blocks, which would be 
randomly assigned to the respondents and every block con-
sisted of one of the better health states and the worst health 
state [24]. This makes for a more balanced way of asking 
Table 3  QOLIBRI-OS summary statistics for the 3 selected VAS 
health states
a Worst possible health state; all attributes have ‘not at all satisfied’ 
level
b Best possible health state; all attributes have ‘very satisfied’ level
Note: rescaled mean for health state 55,555 per country UK (35.56), 
NL (26.07), Italy (49.97)
Health 
state
Obser-
vations 
(N)
Mean VAS SD Rescaled 
mean
Utility mean
Dead 116 38.01 40.71 0.00 0.00
55,555a 138 54.64 33.56 38.26 0.38
11,111b 245 81.49 22.15 100 1
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the questions, because everyone gets a well-balanced set of 
questions, which accounts for the whole range of severity. In 
addition, red-green colour blindness could have influenced 
our respondents while answering the DCE questions; how-
ever, color-coding does improve the results [39]. Building 
upon these findings, it would be recommended for future 
research to provide anchors for the DCE and to use different 
colours than red and green. Since we used a market research 
company to recruit our sample, some individuals might be 
‘professional’ respondents: those who answer a large num-
ber of surveys, and whose responses are not typical for the 
general public and we do not know to what extent our sam-
ples are representative for the population in the three coun-
tries with regard to characteristics other than age, gender and 
educational level. Nonetheless, this study is the first one to 
determine a value set for the QOLIBRI-OS in three differ-
ent European countries and introduced the opportunity to 
compare HRQoL of TBI patients with other (patient) groups. 
Similar studies have been performed for the EQ-5D [25, 32], 
and are used daily in HRQoL research.
Conclusions
By transforming the QOLIBRI-OS into utility scores, we 
have enabled the potential application in economic evalua-
tions and in summary measures of population health, which 
may inform decision-makers on the best interventions and 
strategies for TBI patients.
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